2025-07-10 - Analysis Report
Okay, here's the report on Eli Lilly and Co (LLY) based on the provided data.

## Eli Lilly and Co (LLY) Stock Analysis

**Ticker:** LLY
**Company:** Eli Lilly and Co

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

**Key Metrics:**

*   **LLY Cumulative Return:** 253.49%
*   **VOO Cumulative Return:** 94.92%
*   **Absolute Spread (LLY - VOO):** 155.87%
*   **Spread Range:**
    *   Max: 311.6
    *   Min: -27.3
    *   Current: 155.9
*   **Relative Spread:** 54.1

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The absolute spread of 155.87% indicates a substantial difference in cumulative returns.  The relative spread of 54.1 suggests that the current outperformance is positioned in the middle of its historical range relative to the S&P 500.

**Alpha/Beta Analysis (Rolling 3-Year Periods):**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap (B) |
| :---------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017  | 10.0%   | 56.3%   | -19.0%  | 0.0    | 75.8    |
| 2016-2018  | 39.0%   | 58.6%   | 21.0%   | -0.1   | 103.9   |
| 2017-2019  | 50.0%   | 58.6%   | 20.0%   | 0.3    | 118.0   |
| 2018-2020  | 52.0%   | 58.6%   | 33.0%   | 0.1    | 151.6   |
| 2019-2021  | 106.0%  | 60.6%   | 57.0%   | 0.2    | 248.0   |
| 2020-2022  | 98.0%   | 64.8%   | 96.0%   | 0.2    | 328.4   |
| 2021-2023  | 133.0%  | 64.8%   | 115.0%  | 0.3    | 523.3   |
| 2022-2024  | 150.0%  | 72.2%   | 124.0%  | 0.2    | 693.1   |
| 2023-2025  | 106.0%  | 76.8%   | 60.0%   | 0.2    | 705.1   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has been consistently high, particularly in recent years (2019-2025), indicating strong growth momentum.
*   **MDD:** The Maximum Drawdown has increased over time, suggesting increased volatility or risk.
*   **Alpha:**  The consistently positive and high Alpha values indicate that LLY has generated significant excess returns relative to the market (S&P 500).
*   **Beta:** The Beta values are generally low, suggesting that LLY's price is not highly correlated with the market. A beta near zero suggests the stock's returns are largely independent of market movements.
*   **Cap:** Market capitalization has grown substantially, reflecting the company's strong performance and investor confidence.

### 2. Recent Stock Price Movement

**Key Metrics:**

*   **Current Price:** 785.43
*   **Last Market Data:**
    *   Price: 785.45
    *   Previous Close: 777.66
    *   Change: 1.0
*   **5-Day Moving Average:** 778.83
*   **20-Day Moving Average:** 787.64
*   **60-Day Moving Average:** 778.64

**Analysis:**

The current price is slightly below the 20-day moving average but above the 5-day and 60-day moving averages. The price increased by 1.0 compared to the previous close, indicating a minor upward movement. The fact that the price change is not so big suggests that there aren't any big volatility issues.

### 3. Market Risk Indicators

**Key Metrics:**

*   **Market Risk Indicator (MRI):** 0.3373 (Low Risk)
*   **RSI:** 41.46
*   **PPO:** -0.14
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (3 shares - Caution - MRI:0.35) (Cash Ratio: 0% on 2025-06-05)
*   **20-Day Relative Spread Change:** -3.3 (Negative - Short-term Decline)
*   **Expected Return:** 136.8% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** The MRI of 0.3373 suggests a low-risk environment, which is a positive signal.
*   **RSI:** An RSI of 41.46 indicates that the stock is neither overbought nor oversold, suggesting neutral momentum.
*   **PPO:** A PPO of -0.14 suggests that the short-term moving average is slightly below the long-term moving average, indicating a possible short-term downtrend.
*   **Hybrid Signal:** The hybrid signal recommends buying 80% of cash with caution due to the MRI.
*   **Relative Spread Change:** The negative change in the 20-day relative spread suggests a short-term underperformance relative to the S&P 500.
*   **Expected Return:** The high expected return of 136.8% suggests strong long-term growth potential relative to the S&P 500.

### 4. Recent News & Significant Events

*   **2025-07-07:** Eli Lilly and Co (LLY) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-07-08:** Analysts are discussing Eli Lilly and Co's (LLY) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-07-06:** Eli Lilly and Co (LLY)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-07-10:** Market experts highlight both risks and opportunities for Eli Lilly and Co (LLY), advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news suggests that LLY has been subject to significant market attention, due to notable business developments, regulatory changes, or market events. Investors are advised to monitor recent news and company announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
| :--------- | :---- | :---------- |
| 2025-05-01 | 3.07  | 12.73 B$    |
| 2024-10-30 | 1.08  | 11.44 B$    |
| 2024-08-08 | 3.29  | 11.30 B$    |
| 2024-04-30 | 2.49  | 8.77 B$     |
| 2025-05-01 | 2.49  | 8.77 B$     |

**Analysis:**

*   Earnings per share (EPS) and revenue have shown overall positive growth.
*   The most recent quarter (2025-05-01) shows EPS at 3.07 and revenue at 12.73 B$.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |
| 2024-03-31 | $8.77B     | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| :--------- | :--------- | :-------- |
| 2025-03-31 | $15.76B    | 17.50%    |
| 2024-12-31 | $14.19B    | 31.07%    |
| 2024-09-30 | $14.24B    | 6.81%     |
| 2024-06-30 | $13.56B    | 21.88%    |
| 2024-03-31 | $12.81B    | 17.51%    |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the past year, indicating strong sales performance.
*   **Profit Margin:** Profit margins are consistently high, indicating efficient operations and strong pricing power.
*   **Equity:** Equity has increased, showing growth in the company's net worth.
*   **ROE:** Return on Equity (ROE) fluctuates but remains positive, indicating that the company is effectively using shareholder equity to generate profits.

### 7. 종합적인 분석 (Overall Analysis)

Eli Lilly and Co (LLY) demonstrates strong financial performance and significant outperformance relative to the S&P 500. Here's a summary:

*   **Outperformance:** LLY has significantly outperformed the S&P 500, indicating strong growth and investor confidence.
*   **Financial Health:** The company exhibits increasing revenue, high-profit margins, and a strong ROE, reflecting sound financial management.
*   **Risk:** While the MRI indicates a low-risk environment, investors should monitor recent news and company announcements.
*   **Technical Indicators:** The technical indicators suggest that the stock is currently in a neutral to slightly negative momentum phase, but the long-term expected return remains very high.

**Conclusion:**

LLY presents a compelling investment opportunity, with strong historical performance and promising future growth prospects. However, investors should be mindful of potential risks and keep a close eye on market news.
